12 Health Care Stocks Moving In Monday's After-Market Session

Gainers

• Conformis (NASDAQ:CFMS) shares moved upwards by 13.2% to $0.29 during Monday's after-market session. The company's market cap stands at $53.5 million.
• OKYO Pharma (NASDAQ:OKYO) stock rose 13.08% to $2.68. Trading volume for this security closed at 111.8K, accounting for 101.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $58.3 million.
• Aytu BioPharma (NASDAQ:AYTU) shares rose 11.96% to $0.57. The market value of their outstanding shares is at $21.9 million.
• Cabaletta Bio (NASDAQ:CABA) stock moved upwards by 11.3% to $1.28. The market value of their outstanding shares is at $37.0 million.
• AN2 Therapeutics (NASDAQ:ANTX) stock rose 10.64% to $8.42. The company's market cap stands at $163.3 million.
• AdaptHealth (NASDAQ:AHCO) stock rose 9.86% to $24.5. The company's market cap stands at $3.2 billion.

Losers

• Enhabit (NYSE:EHAB) stock fell 20.0% to $14.38 during Monday's after-market session. The market value of their outstanding shares is at $717.5 million. As per the press release, Q2 earnings came out today.
• Hyperfine (NASDAQ:HYPR) shares declined by 6.21% to $1.21. The market value of their outstanding shares is at $85.1 million.
• Stealth BioTherapeutics (NASDAQ:MITO) stock fell 5.35% to $0.27. This security traded at a volume of 1.0 million shares come close, making up 41.6% of its average volume over the last 100 days. The company's market cap stands at $20.1 million.
• TransMedics Group (NASDAQ:TMDX) shares declined by 5.01% to $39.5. The company's market cap stands at $1.1 billion. As per the news, the Q2 earnings report came out today.
• Dermata Therapeutics (NASDAQ:DRMA) stock declined by 5.0% to $0.55. The company's market cap stands at $5.0 million.
• Macrogenics (NASDAQ:MGNX) stock declined by 4.81% to $2.97. The market value of their outstanding shares is at $182.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.